尽管我们对其分子生物学的理解取得了显着进展，但卵巢癌是所有妇科肿瘤中最致命的。基础治疗仍然是细胞减灭术，然后进行铂类化疗。最近，添加PARP抑制剂等靶向治疗作为一线维持治疗已带来显着的改善，主要是在BRCA突变和同源重组缺陷的肿瘤中。然而，很大一部分患者会出现复发，主要是由于铂类耐药，最终导致死亡。在这些患者中，原发性铂耐药患者的预后尤其糟糕，因为他们对当前可用疗法的反应较低，历史上被排除在临床试验之外，并且缺乏经过验证的生物标志物。在这篇综述中，我们讨论了卵巢癌铂类耐药的概念、这种耐药的临床和分子特征，以及这些患者当前和新的治疗选择。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Ovarian cancer is the most lethal of all the gynecological tumors despite remarkable advances in our understanding of its molecular biology. The cornerstone treatment remains cytoreductive surgery followed by platinum-based chemotherapy. Recently, the addition of targeted therapies, such as PARP inhibitors, as first-line maintenance has led to outstanding improvements, mainly in BRCA mutated and homologous recombination deficient tumors. However, a significant proportion of patients will experience recurrence, primarily due to platinum resistance, which ultimately result in fatality. Among these patients, primary platinum-resistant have a particularly dismal prognosis due to their low response to current available therapies, historical exclusion from clinical trials, and the absence of validated biomarkers. In this review, we discuss the concept of platinum resistance in ovarian cancer, the clinical and molecular characteristics of this resistance, and the current and new treatment options for these patients.Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.